Loading
LB
Landos Biopharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by PERCEPTIVE ADVISORS LLC, was filed 09 Feb 2021.
Landos Biopharma, Inc.: what insiders have been doing
This page follows insider dealings at Landos Biopharma, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Landos Biopharma, Inc. The previous disclosure was published on 2 March 2023.
Looking back to 2021, when coverage begins, insiders filed 8 purchases and 22 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
50
Thresholds
n/a
Buy Volume
€28M
8 ops. · all time
Sell Volume
€3M
22 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$15.5M
Net income-US$18.9M-121.9% margin
Last declaration on 2 March 2023
Declarations50 total
467,306 sharescommon stockSEC:0001843575-23-000002:1
496,527 sharescommon stockSEC:0001843575-23-000002:2
500,000 sharescommon stockSEC:0001843575-23-000002:3
786,299 sharescommon stockSEC:0001843575-23-000002:4
3,470,736 sharescommon stockSEC:0001843575-23-000002:0
300,000 shares@ US$0.69100.0% of flowCommon StockSEC:0000902664-22-004363:0
500,000 shares0common stockSEC:0001843575-22-000003:1
500,000 shares0common stockSEC:0001843575-22-000003:0
24,301 shares@ US$5.114.0% of flowcommon stockSEC:0001843575-21-000010:1
36,000 shares@ US$4.845.7% of flowcommon stockSEC:0001843575-21-000010:2
33,194 shares@ US$4.755.2% of flowcommon stockSEC:0001843575-21-000010:3
58,651 shares0common stockSEC:0001843575-21-000010:0
42,000 shares@ US$5.107.0% of flowcommon stockSEC:0001843575-21-000009:1
43,000 shares@ US$5.027.0% of flowcommon stockSEC:0001843575-21-000009:2
40,000 shares@ US$5.37125.3% of flowcommon stockSEC:0001843575-21-000009:0
40,000 shares@ US$5.777.5% of flowcommon stockSEC:0001843575-21-000008:1
11,162 shares@ US$6.2568.2% of flowcommon stockSEC:0001843575-21-000008:0
42,000 shares@ US$6.589.0% of flowcommon stockSEC:0001843575-21-000007:1
25,530 shares@ US$6.655.5% of flowcommon stockSEC:0001843575-21-000007:2
36,000 shares@ US$6.16626.1% of flowcommon stockSEC:0001843575-21-000007:0
29,861 shares@ US$6.456.3% of flowcommon stockSEC:0001843575-21-000006:1
36,000 shares@ US$6.157.2% of flowcommon stockSEC:0001843575-21-000006:2
934,504 shares0common stockSEC:0001843575-21-000006:3
934,504 shares0common stockSEC:0001843575-21-000006:4
32,237 shares@ US$7.01426.6% of flowcommon stockSEC:0001843575-21-000006:0
25 of 50 declarations
About Landos Biopharma, Inc.
Landos Biopharma, Inc. is a U.S.-based biopharmaceutical company listed on NASDAQ in the United States, operating in the highly specialized autoimmune and inflammatory disease space. The company was historically headquartered in Blacksburg, Virginia, and was built around its proprietary LANCE® platform, an AI-enabled discovery engine designed to identify novel oral therapeutics against differentiated biological targets. Landos’ business model was that of a clinical-stage biotech: enterprise value depended primarily on pipeline advancement, clinical data generation, and regulatory interaction with the FDA rather than on commercial product sales.
At the core of the company’s strategy was the development of oral treatments for patients with autoimmune disorders. Its best-known programs included omilancor, LABP-104, LABP-111, and NX-13, a candidate evaluated in ulcerative colitis. This pipeline reflected a focus on gut-restricted or systemically active small molecules with the potential to offer an oral alternative to biologic therapies. From an investor perspective, that positioning could have been attractive if the clinical profile showed meaningful efficacy, safety, and differentiation versus established standards of care.
Read moreShow less
Landos competed in a crowded and capital-intensive environment dominated by large pharmaceutical companies and a wide set of immunology and gastroenterology specialists. Its competitive edge was not scale, but scientific specialization, intellectual property, and the ability to generate compelling clinical proof points. In other words, this was a catalyst-driven biotech story rather than a mature healthcare franchise.
Geographically, Landos’ operations were centered in the United States, with a historical base in Blacksburg, Virginia, and its equity market visibility tied to NASDAQ. Public disclosures and regulatory activity were U.S.-centric, which is typical for a development-stage biotech with domestic clinical and corporate infrastructure.
The most important recent milestone came in March 2024, when Landos announced a definitive agreement to be acquired by AbbVie. That announcement materially changed the company’s strategic and valuation framework, shifting the investment case from standalone pipeline execution toward acquisition completion and transaction risk. In addition, the SEC Form 4 filings associated with LABP provide ongoing transparency into insider ownership changes, a relevant point for governance and insider-activity analysis.
Overall, Landos Biopharma should be viewed as a U.S. NASDAQ-listed biotech whose story has been defined by autoimmune pipeline development, oral small-molecule innovation, and, more recently, a takeover process that re-shaped the company’s market position.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
